Jagsonpal Pharmaceuticals Limited has fixed May 04, 2026, as the record date for its buy-back of up to 16,00,000 equity shares. The buy-back is priced at ₹250 per share for a total aggregate amount of ₹40 Crore. This event determines shareholder eligibility for participation in the buy-back program.
Jagsonpal Pharmaceuticals Limited granted 1,93,000 employee stock options at an exercise price of Rs. 159.50 each, totaling ₹3.08 Crore. The options vest in four equal annual tranches starting from April 2027. This move aims to align employee interests with long-term shareholder value creation.
Jagsonpal Pharmaceuticals Limited has recommended a dividend of Rs. 4/- (200%) per equity share for the financial year ended March 31, 2026. The dividend is subject to shareholder approval at the upcoming 47th Annual General Meeting. Record and payment dates will be announced separately.
Jagsonpal Pharmaceuticals Limited recommended a final dividend of ₹4 per equity share for the financial year. The record date and AGM date will be announced subsequently upon finalization. This recommendation is subject to shareholder approval at the upcoming Annual General Meeting.
Jagsonpal Pharmaceuticals reported strong FY26 results with 7% revenue growth and 19% PAT growth. Strategy focuses on an asset-light model, high-margin Rx brands, and shareholder returns via buybacks and dividends.
Jagsonpal Pharmaceuticals reported FY26 revenue of ₹287.2 Crore, a 7% YoY increase, with PAT rising 19% to ₹44.6 Crore. The Board approved a ₹40 Crore share buyback at ₹250 per share and proposed a 200% dividend. Growth was driven by strong demand in core therapies like Gynaecology and Orthopaedics.
Jagsonpal Pharmaceuticals reported FY26 total income of ₹299.22 Crore and Net Profit of ₹43.08 Crore. The Board recommended a dividend of ₹4 (200%) per equity share. Additionally, a buy-back of up to 16,00,000 equity shares at ₹250 per share was previously approved, totaling ₹40 Crore.
Jagsonpal Pharmaceuticals Ltd secured shareholder approval for a buyback of up to 16 lakh equity shares at ₹250 each. The transaction, totaling ₹40 Crore, aims to optimize capital allocation and improve earnings per share.
Jagsonpal Pharmaceuticals Limited announced the successful passage of a postal ballot resolution for an equity share buy-back worth ₹40 Crore. Shareholders approved the buy-back of up to 16,00,000 shares at ₹250 per share with a 99.99% majority. The resolution was deemed passed on April 24, 2026.
Jagsonpal Pharmaceuticals Limited has scheduled a Board Meeting on April 27, 2026, to approve audited standalone yearly financial results and recommend a final dividend. The trading window remains closed until April 29, 2026.
Jagsonpal Pharmaceuticals Ltd has scheduled a Board Meeting on April 27, 2026. The board will consider and approve audited financial results for the quarter and year ended March 31, 2026, and evaluate a potential dividend recommendation for the financial year.
Jagsonpal Pharmaceuticals Limited allotted 176,900 equity shares under its ESOP/ESPS scheme on April 13, 2026. This increased the company's paid-up share capital from ₹13.39 Crore to ₹13.43 Crore.
Jagsonpal Pharmaceuticals Limited allotted 1,76,900 equity shares under its JPL ESOP 2022 scheme following the exercise of options by employees. This allotment increased the company's paid-up share capital to ₹13.43 Crore. The shares rank pari-passu with existing equity shares and reflect the company's ongoing employee incentive commitments.
